89
Participants
Start Date
May 31, 2015
Primary Completion Date
July 31, 2016
Study Completion Date
October 31, 2016
SER-109
SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
Placebo
Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Mount Sinai Hospital, New York
University of Rochester Medical Center, Rochester
Drexel University/Hahnemann University Hospital, Philadelphia
Metropolitan Gastroenterolgy Group Pc, Chevy Chase
Anne Arundel Health System Research Institute, Annapolis
Medical Associates of Central Virginia, Lynchburg
Emory University, Atlanta
Advanced Medical Research Center, Port Orange
Omega Research Consultants LLC, DeBary
Borland-Groover Clinic, Jacksonville
ZASA Clinical Research, Atlantis
Gastroenterology Group of Naples, Naples
Remington-Davis, Inc., Columbus
University of Cincinnati College of Medicine, Cincinnati
Regional Infectious Diseases-Infusion Center Inc, Lima
William Beaumont Hospital, Royal Oak
Mayo Clinic, Chatfield
Mercury Street Medical Group, Butte
Sundance Clinical Research, St Louis
Ochsner Clinic Foundation, New Orleans
University of Texas School of Public Health, Houston
Idaho Falls Infection Diseases, Idaho Falls
North County Gastroenterology, Oceanside
Ventura Clinical Trials, Ventura
University Of California Davis, Sacramento
Johns Hopkins Bayview Medical, Baltimore
Massachusetts General Hospital, Boston
Beth Israel Deaconess Med Cntr, Boston
Englewood Hospital and Medical Center, Englewood Cliffs
Brown Alpert Medical School, Providence
Collaborators (1)
Syneos Health
OTHER
Seres Therapeutics, Inc.
INDUSTRY